At a glance
- Originator Eisai Co Ltd
- Class Antithrombotics
- Mechanism of Action PAR 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute coronary syndromes; Coronary disorders
Most Recent Events
- 15 May 2012 Discontinued - Phase-II for Acute coronary syndromes in European Union (PO)
- 15 May 2012 Discontinued - Phase-II for Acute coronary syndromes in Japan (PO)
- 15 May 2012 Discontinued - Phase-II for Acute coronary syndromes in USA (PO)